Isolated limb perfusion: A literature review

Journal of Extra-Corporeal Technology

Volumn 34, Issue 2, 2002, Pages 130-143

  Schaadt, Jennifer ^a,d   Crowley, Richard ^b   Miller, Danielle ^c   Kavanah, Maureen ^a  

^a VA Hospital West Roxbury   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NONE   (United States)

Author keywords

Chemotherapy; Extracorporeal circulation hyperthermia; Isolated limb perfusion; Malignant melanoma

Indexed keywords

ANTICOAGULATION; BIOLOGY; CANCER DIAGNOSIS; CANCER STAGING; CANNULATION; CHEMOTHERAPY; DRUG DELIVERY SYSTEM; EXTRACORPOREAL CIRCULATION; HUMAN; ISOLATED LIMB PERFUSION; LIMB PERFUSION; LITERATURE; MEDICAL PRACTICE; MELANOMA; PATIENT EDUCATION; PATIENT SELECTION; PHYSICIAN; REVIEW; RISK FACTOR; TECHNOLOGY; TOXICITY; TREATMENT INDICATION;

EID: 0036625832     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Krementz ET, Sutherland CM, Muchmore JH. Isolated hyperthermia chemotherapy perfusion for limb melanoma. Surg Clin North Am. 1996;76:1313-30.
2. Hohenberger P, Kettelhack C. Clinical management and current research in isolated limb perfusion for sarcoma and melanoma. Oncology. 1998;5:89-102.
3. Ariyan S, Poo WJ. Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients. Surgery. 1998;123:335-43.
4. Krementz ET, Knudson L. The effect of increased oxygen tension on the tumorcidal effect of nitrogen mustard. Surgery. 1961;50:266-7.
5. Cavaliere R, Ciocatto EC, Giovanella BC, et al. A selective heat sensitivity of cancer cells: Biochemical and clinical studies. Cancer. 1967;20:1351-81.
6. Rossi CR, Foletto M, Vecchiato, et al. Management of cutaneous melanoma MO: State of the art and trends. Eur J Canc. 1998;33:2320-12.
7. Kam PCA, Thompson JF. Anesthetic experience with isolated limb perfusion with melphalan for melanoma. Perfusion. 1996;11:39-399.
8. U.S. Department of Food and Drug Administration. Office of Orphan Products Development. Rockville, MD; 1992. check f27.
9. American Committee on Cancer. AJCC Cancer Staging Manual. Malignant Melanoma of the Skin. Philadelphia: Lippencott-Raven, 1997:163-70.
10. Nagle RB. The use of antikeartin antibodies in the diagnosis of human neoplasma. Am J Clin Pathol. 1983;79:458.
11. Asada M. Solid basal cell epitheliomas possibly originates from the outer root sheath of the hair follicle. Acta Derm Venereol. (Stockh). 1993;73:286.
12. D'Errico M, Dogliotti E. The role of p53 mutations in skin cancer. Chron Dermatol. (Roma). 1996;6:27.
13. Spencer JM. Activated rat genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol. 1995;131:792.
14. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: Incidence. J Am Acad Dermatol. 1994;30:774.
15. Langely RGB, Barnhill RL, Mihm MG, et al. Neoplasms: Cutaneous melanoma. In: Clinical Dermatology. Freedberg IM, Eisen AZ, Wolff K, eds. New York: McGraw-Hill, 1999;1080-116.
16. Rhodes AR, et al. Risk factors for cutaneous melanoma: A practical method for recognizing predisposed individuals. JAMA. 1987;258:3146.
17. Elwood JM. Melanoma and sun exposure. Semin Oncol. 1996;23:650.
18. Pappa AS, et al. Childhood melanoma. In: Cutaneous Melanoma. Balch CM, ed. St Louis: Quality Medical, 1998;175-86.
19. Ceballus PI, et al. Melanoma in children. N Engl J Med. 1995;332:656.
20. Koh HK, et al. Evaluation of the American Academy of Dermatology's national skin cancer early detection and screening program. J Am Acad Dermatol. 1996;34.
21. Friedman RJ, Rigel SD, Kopf AW. Early detection of malignant melanoma: The role of physician examination and self-examination of the skin. CA Cancer J Clin. 1985;35:140-51.
22. Anderson B, Ostberg J. Long-term prognosis in geriatric surgery. J Am Geriatr Soc. 1972;20:255.
23. Clark WH, From L, Bernadino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:70.
24. Breslow K. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902.
25. Jacques DP, Coit DG, Brennan MF. Major amputation for advanced melanoma. Surg Gynecol Obstet. 1989;169:1-6.
26. Hafstrom L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol. 1991;9:2091-4.
27. Klaase JM, Kroon BB, van Geel AN, et al. Prognostic factors for tumor response and limb recurrence free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery. 1994;115:39-44.
28. Stanley G, Sundarakumara R, Crowley R, et al. Desflurane as a marker of limb to systemic leak during hyperthermic isolated limb perfusion. Anesth. 2000;93:574-6.
29. Fried SJ, Miller R, Weaver F. Safe, compact, and portable system for regional chemotherapeutic hyperthermic perfusion procedures. J Extra-Corp Technol. 1993;25:22-6.
30. Pfefferkorn RO, Didolkar MS. Regional perfusion for melanoma of the extremities. J ExtraCorp Technol. 1982;3:475-9.
31. Polk HC. Surgical progress and understanding in the treatment of melanoma epidemic. Am J Surg 1999;178:445-8.
32. Ghussen F, Nagel K, Groth W, et al. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg. 1984;200:764-8.
33. DeBois W, Sukhram Y, McVey J, et al. Reduction in homologous blood transfusions using a low prime circuit. J Extra-Corp Technol. 1996;28:58-60.
34. O Gara P, Treanor P, Lilly K, et al. Technique for routine use of heparin-bonded circuits with a reduced anticoagulation protocol. J Extra-Corp Technol. 2000;4:207-13.
35. von Segesser LK, Weiss BK, Pasic M, et al. Risks and benefits of lower systemic heparinization during open-heart operations. Ann Thorac Surg. 1999;58:391-8.
36. Aldea GS, Doursounian M, O'Gara P, et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: A prospective randomized study. Ann Thorac Surg. 1996;62:410-8.
37. Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. J Clin Oncol. 1998;16:2906-12.
38. Crutchely OM, Kaplan JA, Waller JL, et al. Anesthesia for isolated hyperthermic limb perfusion. Anesthesiology. 1982;57:228-30.
39. Thomspon JF, Hunt JA, Shannon KF, et al. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 1997;132:904-7.
40. Edwards MJ, Soong SJ, Boddie AW, et al. Isolated limb perfusion for localized melanoma of the extremity. Arch Surg. 1990;125:317-22.
41. Cavaliere R, Cavaliere F, Deraco M, et al. Hyperthermic antiblastic perfusion in the treatment of stage IIIA-IIIAB melanoma patients: Comparison of two experiences. Melanoma Res. 1994;4(Suppl 1):5-11.
42. DiFilippo FV, Calabro A, Ciannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer. 1989;63:2551-61.
43. Chabner BA, Wilson W. Pharmacology and toxicity of antineoplastic drugs. In: Williams Hematology. Beutler E, ed. New York: McGraw-Hill, 1995;143-55.
44. Kopf AW, et al. Thickness of malignant melanoma: Global analysis of related factors. J Dermatol Surg Oncol. 1987;13:345.
45. Boddie AW, Briele H, Krementz E, et al. A phase I study of melphalan in 40°C isolated limb perfusion using packed red blood cells and lactated Ringer's perfusate. Proc Am Soc Clini Oncol. 1992;11:A1208.
46. Taber SW, Polk HC. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Ann Surg Oncol. 1997;5:440-5.
47. Weksler B, Burt M. Isolated lung perfusion with antineoplastic agents for pulmonary metastases. Chest Surg Clin North Am. 1998;8:157-82.
48. Vaglini M, Bacci G, Baldini M. Limb salvage in osteogenic sarcoma of extremities a new therapeutic approach associated infusion and hyperthermic antiblastic perfusion. J Extra-Corp Technol. 1987;19:338-47.
49. Cosary CL, et al. SEET Cancer Statistics Review, 1973-1992: National Cancer Institutes. NRH Pub 96-2789, Bethesda, MD, 1995.
50. Creech O, Krementz ET, Ryan RF, et al. Chemotherapy of cancer: Regional perfusion utilizing and extracorporeal circuit. Ann Surg. 1958;148:616-32.
51. Krementz ET, Ryan RF, Carter RD, et al. Hyperthermic regional perfusion for melanoma of the limbs. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. Balch CM, Milton GW, eds. Philadelphia: Lippincott, 1985:171-95.
52. Schwemmle K, Aigner K, eds. Vascular Perfusion in Cancer. New York: Springer, 1083.